Platforms-Leads Biolabs

Platforms

Home

Innovation

LeadsBody

(CD3 T-Cell Engager platform)

To achieve an optimal balance between safety and efficacy of T-cell engagers, we have developed a proprietary LeadsBody platform capable of facilitating diverse modifications to molecular designs of CD3-targeted bispecific antibodies. These key modifications include:

Variable expression levels which controls how strongly the antibodies bind to tumor-associated antigens (TAA)

Fine-tuning CD3 affinity with differentiated profiles of cytokine release

Conditional T-cell redirecting and activation mechanisms within tumor microenvironments

Differing spatial structures

Platform possesses these significant advantages:

Optimized proportions and affinities of TAA and CD3 binding domains directing the action of T-cell engagers to the tumor site, minimizing off-target toxicity

Structural optimizations inducing effective killing of target cells by T cells while reducing cytokine secretion

Both in vitro and in vivo studies, T-cell engagers exhibited durable antitumor effects with less T-cell exhaustion induction

X-body

(4-1BB Engager platform)

Our X-body platform leverages advanced antibody engineering technology to create differentiated bispecific antibodies in a 2:2 format with high yield, high purity and excellent druggability.

One achievement that came out of our X-body platform is Opamtistomig (LBL-024), a 4-1BB/PD-L1 bispecific antibody. Our unique molecular design enables to overcome the major hurdle of liver toxicity associated with 4-1BB, and to achieve synergistic antitumor effects through both immune activation and the alleviation of immune suppression.

Balance the affinity between tumor-associated antigens (TAA) and 4-1BB

Facilitate the crosslinking and activation of the 4-1BB receptor only when binding to TAA at tumor sites, thereby localizing 4-1BB activation in TAA expressing tumor microenvironment

Bolster the immune response within the tumor microenvironment, while mitigating the risk of systemic toxicities

TOPiKinectics

(ADC platform)

Our proprietary TOPiKinectics platform possesses these significant advantages:

Strong target binding and rapid internalization

Fc mutation and precise control of DAR to balance efficacy and toxicity

Bystander killing to address tumor heterogeneity

Stable conjugator without retro-Michael reaction

Improved ADC physicochemical property

A portfolio of Next-Gen ADC developed on TOPiKinectics platform

LBL-056: a next-generation dual Payload Bi-specific ADC

LBL-061：a next-generation bispecific ADC targeting both EGFR and PD-L1

LBL-081: a next-generation PD-L1 based Bi-specific ADC

ImBiTDC (TDC Platform)

LeadsBiolabs has independently developed the world's first innovative technology platform for T Cell Engager Drug Conjugate (TDC). Based on the company's proprietary antibody platform and TOPiKinectics (ADC technology platform), it deeply integrates the tumor-specific antigen-targeting TCE module with ADC technology, creating a next-generation solid tumor immunotherapy technology platform that combines the potent anti-tumor immune activity of TCE with the precise targeted killing characteristics of ADC.

Through the innovative integration of TCE and ADC technologies, it can increase tumor response rates, prolong patient survival, and reduce immune-related adverse reactions, establishing a novel technological paradigm for solid tumor immunotherapy.

Primary mechanism of action

Through ADC, it can specifically bind to tumor cells, release toxic payloads after internalization, directly induce tumor cell apoptosis, and exert a bystander effect; in addition, it can lyse tumor cells through the T cell redirection killing mechanism of TCE.

The ADC mechanism induces immunogenic cell death, via releasing damage-associated molecular patterns (DAMPs), and remodeling the tumor microenvironment. This process will further enhance TCE-mediated TDCC, forming a synergistic cycle between ADC and TCE, while increasing the degree of T cell infiltration and activation status.

Core advantages of the platform

Broad-spectrum efficacy

Not limited by the single mechanism of ADC or TCE, it can adapt to tumor scenarios with various T-cell infiltration levels, T cell functional status, and antigen expression abundance. It can not only efficiently kill tumors with high antigen expression and high sensitivity to payload but also cover patient populations with low antigen levels and immunosuppressive phenotypes through the bystander effect and T -cell redirection, significantly expanding the eligible patient population.

Safety optimization

Compared with TCE monotherapy, it significantly reduces the risk of CRS, thereby improving safety while enhancing anti-tumor efficacy.

Next-generation tumor immunotherapy pipeline based on the TDC platform

LBL-054: CDH17-targeting TDC for the treatment of gastrointestinal tumors

LBL-058: DLL3-targeting TDC for the treatment of small cell lung cancer and neuroendocrine tumors